top of page
Home
Our Science
Our Clinical Trials
The KTX-1001 Program
The KTX-2001 Program
Expanded Access Policy
About Us
Leadership
Board of Directors
Scientific Advisory Board
Clinical Advisory Board
Investors
News & Events
Press Releases
Contact Us
More
Use tab to navigate through the menu items.
Latest News
2
3
1/3
Press Release
Anti-adhesion properties of KTX-1001, a selective NSD2/MMSET inhibitor, enhance Carfilzomib sensitivity in multiple myeloma
High Expression of NSD2 in non-t(4;14) newly-diagnosed multiple myeloma patients may mimic t(4;14) biology
Press Release
August 7, 2025
K36 Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for KTX-2001 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Announces Clinical Trial Collaboration with Bayer for Supply of Darolutamide
​KTX-2001 is Company’s second selective inhibitor of NSD2 to enter the clinic
Read More
August 6, 2025
K36 Celebrates Scientific Founder Dr. Or Gozani's Publication in Nature Elucidating NSD2's Critical Role in Oncogenesis and Epigenetic Regulation
NSD2 inhibitors rewire chromatin to treat lung and pancreatic cancers | Nature
Read More
July 2025
Executive Director Chad Lewis Leads K36 Team in Publishing Critical NSD2 Research in Journal of Biological Chemistry
Characterization of the activity of KTX-1001, a small molecule inhibitor of multiple myeloma SET domain using surface plasmon resonance
Read More
December 2024
K36 Therapeutics Announces Presentation on KTX-1001 for Relapsed and Refractory Multiple Myeloma at the 66th American Society of Hematology (ASH) Annual Meeting
Multiple posters to be presented
Read More
View Older Posts
Media Contact
info@k36tx.com
bottom of page
